cardiokinetix

CardioKinetix Announces Successful Parachute Live Case Transmission at 2013 EuroPCR Conference May 24, 2013

Paris and Menlo Park, Calif – CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart failure, today announced the transmission of a live satellite feed of a clinical case using the first-of-its-kind catheter-based Parachute^® Device at the annual 2013 EuroPCR Conference in Paris

The Parachute procedure was performed

CardioKinetix Announces Positive Clinical Data Showing Consistent Compelling Positive Results for Patients Treated with Minimally Invasive Structural Heart Device for Heart Failure May 22, 2013

Meta-Analysis Presented at EuroPCR Substantiate Potential of Breakthrough Treatment for Heart Failure Patients; Largest Group Studied to Date

Paris and Menlo Park, Calif — CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart failure, today announced results of a meta-analysis study of the first-of-its-kind

CardioKinetix Initiates Landmark Study of First-of-Its-Kind Treatment for Heart Failure in the United States January 8, 2013

Randomized Multicenter PARACHUTE IV Clinical Trial Will Compare Minimally Invasive Device to Optimal Medical Therapy

Menlo Park, Calif — CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart failure, announced the enrollment of the first patients in PARACHUTE IV, the randomized pivotal

CardioKinetix Announces Successful Live Case Transmission at TCT 2012 Conference October 25, 2012

Menlo Park, Calif and Miami, Fla – CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart failure, today announced the transmission of a live satellite feed of a clinical case using the first-of-its-kind catheter-based Parachute™ Ventricular Partitioning Device to an audience of several hundred interventional cardiologists at

CardioKinetix Announces Data from Latest European Study of Heart Failure Patients with First-of-Its-Kind Percutaneous Treatment October 24, 2012

Positive Six-Month and Three-Year Results Presented at TCT 2012 Demonstrate Meaningful and Sustained Improvement in Clinical Outcomes for Heart Failure Patients

Menlo Park, Calif – CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart failure, today announced clinical results showing meaningful and sustained

CardioKinetix Receives CE Mark Approval for Full Range of Sizes for First-of-Its-Kind Percutaneous Treatment for Heart Failure October 23, 2012

Menlo Park, Calif – CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart failure, today announced it has received CE Mark approval for the full size matrix of  the company’s Parachute™ Ventricular Partitioning Device for Percutaneous Ventricular Restoration (PVR) therapy

“The CE Mark approval for the full

CardioKinetix Chosen as One of FierceMedicalDevices’ “Fierce 15” Medical Device and Diagnostic Companies of 2012 October 2, 2012

Award Presented at AdvaMed 2012: The MedTech Conference

Menlo Park, Calif – CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart failure, today announced that the company has been named to the FierceMedicalDevices “Fierce 15” list, designating it as one of the leading medical device and diagnostic companies

CardioKinetix Announces Positive Three-Year Clinical Data for First-of-Its-Kind Minimally August 27, 2012

Results Presented at European Society of Cardiology Demonstrate Meaningful and Sustained Improvement in Clinical Outcomes for Heart Failure Patients

Munich, Germany and Menlo Park, Calif – CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart failure, today announced clinical results showing meaningful and sustained low

CardioKinetix Initiates European Post-Market Trial of First-of-Its-Kind Minimally Invasive Treatment for Heart Failure in Germany June 8, 2012

PARACHUTE III Clinical Trial Will Evaluate Benefits of Therapy in Real-World Setting

Menlo Park, Calif – CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart failure, announced today that it has begun enrollment in PARACHUTE III, a post-market safety surveillance trial, in Germany with the CE Marked

CardioKinetix Announces Positive Two-Year Clinical Data for First-of-Its-Kind Minimally Invasive Treatment for Heart Failure May 18, 2012

Results Presented at EuroPCR Demonstrate Meaningful and Sustained Improvement in Clinical Outcomes, Suggesting Breakthrough Treatment for Heart Failure Patients

Paris and Menlo Park, Calif — CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart failure, today announced two-year clinical results for the first-of-its-kind catheter-based Parachute™

Maria Sainz Joins CardioKinetix as President and Chief Executive Officer May 7, 2012

Brings Proven Record of Success in Commercializing Innovative Therapies

Menlo Park, Calif – CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart failure, announced today that Maria Sainz has joined the company as president and chief executive officer  A veteran medical device executive, Maria brings

CardioKinetix Announces Late Breaking EuroPCR Session Featuring First-of-Its-Kind Minimally Invasive Treatment for Heart Failure May 7, 2012

Two-Year Data on Breakthrough Treatment to be Presented on Friday, May 18

Menlo Park, Calif — CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart failure, today announced that clinical trial data from the first-of-its-kind Parachute™ Ventricular Partitioning Device for the treatment of patients with

CardioKinetix Wins Edison Award for the Parachute Ventricular Partitioning Device April 27, 2012

Awards Honor Innovation, Creativity and Ingenuity

Menlo Park, CA – CardioKinetix Inc, a pioneer in catheter-based treatments for heart failure, today announced that the first-of-its-kind Parachute™ Ventricular Partitioning Device has received an Edison Award in the Surgical Aid (Medical Device) category, one of the fifteen categories honored annually by the

CardioKinetix Demonstrates Positive Results in German Sub-Study using the Parachute™ for Percutaneous Ventricular Restoration Therapy in the Treatment of Ischemic Heart Failure March 8, 2012

Menlo Park, CA — CardioKinetix Inc, a medical device company that has developed a novel transcatheter implant called the Parachute^TM Ventricular Partitioning Device (Parachute^TM),  announced today that a German sub-study from the PARACHUTE Cohort B trial continued to show positive results after heart failure patients were treated with the

CardioKinetix Receives Expanded CE Mark Approval for World’s First Percutaneous Left Ventricular Partitioning Device, the Parachute™, for Treatment of Ischemic Heart Failure January 30, 2012

Menlo Park, CA – CardioKinetix Inc, a medical device company that has developed a novel transcatheter implant called the Parachute™ Ventricular Partitioning Device (Parachute™), announced today that it has received CE Mark approval for two additional sizes of the Parachute™ implant

First Patients in Portugal, Latvia, Slovenia, and the United Kingdom Treated with CardioKinetix’s Parachute Ventricular Partitioning Device January 5, 2012

Menlo Park, CA – CardioKinetix Inc, a medical device company that has developed a novel transcatheter implant called the Parachute™ Ventricular Partitioning Device (Parachute™), announced today that the first patients in Portugal, Latvia, Slovenia and the United Kingdom have been treated with the Parachute™ implant as part of

CardioKinetix Inc. Raises $44 Million in Series E Financing September 20, 2011

MENLO PARK, CA – CardioKinetix Inc, a medical device company that has developed a novel transcatheter implant called the PARACHUTE™ Ventricular Partitioning Device (PARACHUTE™), announced today that it has raised $44 million in a two-tranche Series E financing The financing was led by new investors SV Life Sciences